Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

PHASE2TerminatedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

October 24, 2016

Primary Completion Date

September 19, 2018

Study Completion Date

September 19, 2018

Conditions
Non-alcoholic Steatohepatitis NASH
Interventions
DRUG

LMB763

Hard Gelatin Capsules

DRUG

Placebo

Hard Gelatin Capsule

Trial Locations (30)

1211

Novartis Investigative Site, Geneva

2025

Novartis Investigative Site, Papatoetoe

2305

Novartis Investigative Site, New Lambton

3010

Novartis Investigative Site, Bern

3110

Novartis Investigative Site, Tauranga

6009

Novartis Investigative Site, Nedlands

6021

Novartis Investigative Site, Wellington

6900

Novartis Investigative Site, Lugano

8024

Novartis Investigative Site, Christchurch

11941

Novartis Investigative Site, Amman

23602

Novartis Investigative Site, Newport News

27265

Novartis Investigative Site, High Point

32803

Novartis Investigative Site, Orlando

32806

Novartis Investigative Site, Orlando

33166

Novartis Investigative Site, Miami Springs

37211

Novartis Investigative Site, Nashville

70808

Novartis Investigative Site, Baton Rouge

76012

Novartis Investigative Site, Arlington

77081

Novartis Investigative Site, Houston

90230

Novartis Investigative Site, Culver City

90630

Novartis Investigative Site, Cypress

96814

Novartis Investigative Site, Honolulu

32610-0277

Novartis Investigative Site, Gainesville

02114

Novartis Investigative Site, Boston

0112

Novartis Investigative Site, Tbilisi

Unknown

Novartis Investigative Site, Auckland

00927

Novartis Investigative Site, San Juan

PL6 8DH

Novartis Investigative Site, Plymouth

G31 2ER

Novartis Investigative Site, Glasgow

PO6 3LY

Novartis Investigative Site, Portsmouth

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY